Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to determine the safety and efficacy of an oral Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 6636) as a single agent in Adult Patients With Squamous Cell Carcinoma of the Head & Neck and will help determine if further development is justified.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically or cytologically proven squamous cell carcinoma of the head & neck.
Age greater than or equal to 18.
ECOG performance status of 0 to 1
Measurable malignant disease.
Patients that have failed at least one platinum-containing regimen and have received no more than three prior regimens and do not have other curative treatment options.
Patients must be at least 2 wks post surgery or radiation therapy
Patients must be at least 4 weeks post chemotherapy
Meets protocol requirements for specified laboratory values.
Written informed consent and cooperation of patient.
Appropriate use of effective contraception if of childbearing potential.
No investigational drugs of any type within 30 days prior to administration.
Prior exposure to farnesyl transferase inhibitors
Medical conditions that would interfere with taking oral medications.
Patients with significant QTc prolongation at baseline (>500 msec.)
Pregnant or nursing women
Known HIV positivity or AIDS-related illness.
Concomitant chemotherapy, hormonal therapy, radiotherapy or immunotherapy
Patients with any signs of involvement of the dura, meninges, or brain.
Patients with squamous cell carcinoma of the nasopharynx
Patients who currently have other cancers or have been treated in the last 5 years for any other malignancy.